|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Multivariate analyses showed that NAT1 and TWIST1 staining was significantly associated with EMT status regardless of the estrogen receptor status of the tumors (p values: 0.020 and 0.027, respectively).
|
30610490 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
When stratifying by smoking status, no statistically significant differences in BCa risk were found for NAT1*10 versus non-NAT1*10 acetylators among the different subgroups.
|
29258340 |
2018 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Arylamine N-acetyltransferase 1 (NAT1) is a drug metabolizing enzyme that has been associated with cancer cell proliferation in vitro and with survival in vivo.
|
29969986 |
2018 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Human NAT1 is associated with endogenous metabolic pathways of cells and is a candidate drug target for cancer.
|
29950659 |
2018 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
NAT1 expression showed a trimodal distribution in breast cancer samples (n = 1980) but not in tumor tissue from ovarian, prostate, cervical or colorectal cancers.
|
29969986 |
2018 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There was no association between NAT1*10 allele and bladder cancer risk in a random-effects model (OR = 0.96, 95% CI, 0.84-1.10) or in a fixed-effects model (OR = 0.95, 95% CI, 0.87-1.03).
|
28604993 |
2017 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In contrast to the Berlin study from 2001, data in present study demonstrated that NAT1*10 haplotype was not associated with a significantly decreased bladder cancer risk.
|
28696911 |
2017 |
|
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There was no association between NAT1*10 allele and bladder cancer risk in a random-effects model (OR = 0.96, 95% CI, 0.84-1.10) or in a fixed-effects model (OR = 0.95, 95% CI, 0.87-1.03).
|
28604993 |
2017 |
|
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In contrast to the Berlin study from 2001, data in present study demonstrated that NAT1*10 haplotype was not associated with a significantly decreased bladder cancer risk.
|
28696911 |
2017 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The expression levels of the up-regulated genes (NAT1, BBS1 and PH-4) were also found to be correlated to epithelial to mesenchymal transition status of the tumour.
|
26965286 |
2016 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The incidence of bladder cancer is closely associated with exposure to aromatic amines, that can cause cancer only after metabolic activation regulated by N-acetyl transferase 1 and 2 (NAT1 and NAT2).
|
26681036 |
2015 |
|
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
The incidence of bladder cancer is closely associated with exposure to aromatic amines, that can cause cancer only after metabolic activation regulated by N-acetyl transferase 1 and 2 (NAT1 and NAT2).
|
26681036 |
2015 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In a case-only analysis, frequent red meat consumption was associated with a significantly increased cancer risk for NAT2 slow/intermediate acetylators in the Mixed Ancestry population (OR = 3.55; 95% CI 1.29-9.82; P = 0.019), whereas daily white meat intake was associated with an increased risk among NAT1 slow/intermediate acetylators in the Black population (OR = 1.82; 95% CI 1.09-3.04; P = 0.023).
|
25886288 |
2015 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The incidence of bladder cancer is closely associated with exposure to aromatic amines, that can cause cancer only after metabolic activation regulated by N-acetyl transferase 1 and 2 (NAT1 and NAT2).
|
26681036 |
2015 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Human NAT1-specific inhibitors may act in biomarker detection in breast cancer and in cancer therapy.
|
24467436 |
2014 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Levels of expression of NAT1 were positively correlated with those of ERα (P < 0.0001) and PgR (P < 0.0001), but negatively correlated with both tumor grade and size (P < 0.0001).
|
25528056 |
2014 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that there was no association between the NAT1*10 allele and bladder cancer risk.
|
23569127 |
2013 |
|
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that there was no association between the NAT1*10 allele and bladder cancer risk.
|
23569127 |
2013 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We undertook this study to check whether polymorphisms at NAT1 can modulate the risk of oral leukoplakia and cancer either alone or in combination with NAT2.
|
23168701 |
2012 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
NAT1 is up-regulated in several cancer types, and overexpression can lead to increased survival and resistance to chemotherapy.
|
22090474 |
2012 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
We evaluated the association between hair dye use and bladder cancer risk and effect modification by N-acetyltransferase-1 (NAT1), NAT2, glutathione S-transferase Mu-1 (GSTM1) and glutathione S-transferase theta-1 (GSTT1) genotypes in a population-based case-control study of 1193 incident cases and 1418 controls from Maine, Vermont and New Hampshire enrolled between 2001 and 2004.
|
21678399 |
2011 |
|
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
We evaluated the association between hair dye use and bladder cancer risk and effect modification by N-acetyltransferase-1 (NAT1), NAT2, glutathione S-transferase Mu-1 (GSTM1) and glutathione S-transferase theta-1 (GSTT1) genotypes in a population-based case-control study of 1193 incident cases and 1418 controls from Maine, Vermont and New Hampshire enrolled between 2001 and 2004.
|
21678399 |
2011 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the expression rate of NAT1 mRNA was lower in the tumors from the resistant group than in control tumors (28.6% vs. 65.2%, p = 0.031).
|
20628863 |
2010 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There were no associations between bladder cancer risk and NAT1 genotype or CYP1A2 phenotype.
|
18544563 |
2008 |
|
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There were no associations between bladder cancer risk and NAT1 genotype or CYP1A2 phenotype.
|
18544563 |
2008 |